Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628554 | 0.89 | S1PR3 (0.49) | LMNATSHRCYP2C9ADRA2ACYP2D6 | |
| SCHEMBL6630509 | 0.88 | S1PR3 (0.54) | LMNATSHRCYP2C9ADRA2ACYP2D6 | |
| SCHEMBL4421524 | 0.87 | S1PR3 (0.56) | LMNATSHRCYP2C9ADRA2ACYP2D6 | |
| SCHEMBL6628635 | 0.86 | HTT (0.52) | LMNATSHRCYP2C9ADRA2ACYP2D6 | |
| SCHEMBL4418726 | 0.84 | SLC6A9 (0.54) | LMNATSHRCYP2C9ADRA2ACYP2D6 | |
| SCHEMBL6630760 | 0.82 | SLC6A9 (0.49) | LMNATSHRCYP2C9ADRA2ACYP2D6 | |
| SCHEMBL3220624 | 0.82 | SMN1; SMN2 (0.57) | LMNATSHRCYP2C9ADRA2ACYP2D6 | |
| SCHEMBL385093 | 0.80 | MAPT (0.51) | CYP2C9CYP2D6SMN1; SMN2HSP90AA1MAPT | |
| SCHEMBL4422116 | 0.79 | EPAS1 (0.43) | LMNATSHRCYP2C9ADRA2ACYP2D6 | |
| SCHEMBL13392322 | 0.78 | ALDH1A1 (0.45) | CYP2C9SMN1; SMN2HSP90AA1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368352-B1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LTD (GB) | 2004-12-01 | — | — | EP | claimed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | claimed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | claimed |
| EP-1368352-B1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LTD (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| EP-1368352-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2003-12-10 | — | — | EP | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002074774-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | LMNA 2151/4885TSHR 2374/4885CYP2C9 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.